29 transactions on file, per SEC Form 4 filings.
See CORT superinvestor activity →Maduck Sean
See Remarks · 2026-09-02
Tax withholding
$13K
Mokari Atabak
Chief Financial Officer · 2026-09-02
Tax withholding
$12K
Robb Gary Charles
Chief Business Officer · 2026-09-02
Tax withholding
$10K
Vieira Roberto Wandenkolk
President, Oncology · 2026-09-02
Tax withholding
$12K
Vieira Roberto Wandenkolk
President, Oncology · 2026-09-02
Option exercise
$1.3M
Vieira Roberto Wandenkolk
President, Oncology · 2026-09-02
Sold
$2.6M
Vieira Roberto Wandenkolk
President, Oncology · 2026-09-02
Sold
$2.6M
Vieira Roberto Wandenkolk
President, Oncology · 2026-09-02
Sold
$171K
Vieira Roberto Wandenkolk
President, Oncology · 2026-09-02
Sold
$109K
Vieira Roberto Wandenkolk
President, Oncology · 2026-09-02
Sold
$183K
Vieira Roberto Wandenkolk
President, Oncology · 2026-09-02
Sold
$644K
Vieira Roberto Wandenkolk
President, Oncology · 2026-09-02
Sold
$141K
Lyon Joseph Douglas
See Remarks · 2026-09-02
Tax withholding
$8K
Guyer William
Chief Development Officer · 2026-09-01
Award
$19K
Guyer William
Chief Development Officer · 2026-09-01
Award
164 sh
Maduck Sean
See Remarks · 2026-09-01
Option exercise
$207K
Maduck Sean
See Remarks · 2026-09-01
Sold
$1.3M
Maduck Sean
See Remarks · 2026-09-01
Sold
$1.3M
Maduck Sean
See Remarks · 2026-09-01
Sold
$264K
Maduck Sean
See Remarks · 2026-09-01
Award
$17K
Maduck Sean
See Remarks · 2026-09-01
Award
150 sh
Mokari Atabak
Chief Financial Officer · 2026-09-01
Award
$16K
Mokari Atabak
Chief Financial Officer · 2026-09-01
Award
138 sh
Robb Gary Charles
Chief Business Officer · 2026-09-01
Award
$19K
Robb Gary Charles
Chief Business Officer · 2026-09-01
Award
164 sh
Vieira Roberto Wandenkolk
President, Oncology · 2026-09-01
Award
$16K
Vieira Roberto Wandenkolk
President, Oncology · 2026-09-01
Award
138 sh
Lyon Joseph Douglas
See Remarks · 2026-09-01
Award
$15K
Lyon Joseph Douglas
See Remarks · 2026-09-01
Award
130 sh
Each row links to the underlying SEC filing. Sells are shown for transparency, not as a signal — see the insider trading article for why.
Following an insider into a stock isn't a strategy on its own. Run your own margin-of-safety analysis, free.
Analyze CORT